
Cell-Based Product Development Group, develops high-accuracy preclinical models for rare diseases, cancer, and neurodegenerative disorders using organoids derived from pluripotent stem cells and zebrafish models. These models serve as effective tools for drug efficacy testing and therapeutic design. Additionally, by integrating stem-cell- based therapeutic approaches, gene-editing techniques, and immune-response studies, the group builds a strong bridge from basic science to translational applications.